Marker Therapeutics (NASDAQ:MRKR) Releases Earnings Results, Beats Expectations By $0.02 EPS

Marker Therapeutics (NASDAQ:MRKR) released its earnings results on Friday. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02, FiscalAI reports. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 80.86%. The firm had revenue of $0.75 million for the quarter, compared to the consensus estimate of $0.68 million.

Marker Therapeutics Price Performance

NASDAQ:MRKR traded down $0.04 during trading hours on Friday, reaching $1.42. The company had a trading volume of 28,062 shares, compared to its average volume of 234,915. The firm has a market cap of $23.67 million, a PE ratio of -1.67 and a beta of 1.43. The business’s 50 day moving average price is $1.44 and its 200-day moving average price is $1.43. Marker Therapeutics has a 1-year low of $0.81 and a 1-year high of $4.07.

Hedge Funds Weigh In On Marker Therapeutics

A number of hedge funds have recently modified their holdings of the business. Jane Street Group LLC acquired a new stake in shares of Marker Therapeutics during the 2nd quarter worth about $33,000. Virtu Financial LLC purchased a new stake in shares of Marker Therapeutics in the third quarter valued at approximately $25,000. Two Sigma Investments LP purchased a new stake in shares of Marker Therapeutics in the third quarter valued at approximately $33,000. XTX Topco Ltd boosted its position in Marker Therapeutics by 166.6% during the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after purchasing an additional 36,269 shares in the last quarter. Finally, LPL Financial LLC raised its holdings in shares of Marker Therapeutics by 41.7% in the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock worth $124,000 after acquiring an additional 24,500 shares during the last quarter. 22.39% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Marker Therapeutics in a report on Friday, March 27th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Marker Therapeutics currently has a consensus rating of “Hold” and an average target price of $10.00.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.